Alzinova participates in several industry and investor events during autumn 2025
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Alzinova AB (publ) (Nasdaq First North: ALZ) today announces that the company will participate in several industry and investor events during autumn 2025. The purpose is to present the company’s recent progress and strengthen the dialogue with potential partners and investors.
Over the past year, Alzinova has continued to advance the development of its vaccine candidate ALZ-101 for early Alzheimer’s disease through important scientific and regulatory milestones. As part of the company’s ongoing efforts to strengthen its international presence, Alzinova will during autumn 2025 attend a number of events, providing the opportunity to further develop discussions with potential partners and investors regarding the company’s latest progress.
Alzinova intends to participate in the following events this autumn:
DNB Carnegie Småbolagsdagen – Stockholm, 1 September 2025. Organized by DNB Carnegie.
Investing in Life Science – BioStock – Stockholm, 23 September 2025. Organized by BioStock, https://biostock.se/event/investing-in-life-science/
BioJapan – Yokohama, Japan, 8-10 October 2025. Organized by BioJapan, https://jcd-expo.jp/en/
Redeye Theme: Neurology – Stockholm, 15 October 2025. Organized by Redeye, https://www.redeye.se/events/1110219/redeye-theme-neurology-3?tab=abouttheevent
BIO Europe – Vienna, 3-5 November 2025. Organized by EBD Group, https://informaconnect.com/bioeurope
Redeye Life Science Day 2025 – Stockholm, 3 December 2025. Organized by Redeye, https://www.redeye.se/events/1111918/redeye-life-science-day-2025
.
A complete and updated overview of Alzinova’s planned events can always be found on our website: https://www.alzinova.com/upcoming-events/.
For further information, please contact:
Tord Labuda, CEO
E-mail: info@alzinova.com
About Alzinova AB
Alzinova AB is a Swedish biopharmaceutical company in clinical development specializing in the treatment of Alzheimer's disease, where the starting point is to attack toxic amyloid-beta oligomers. The lead candidate ALZ-101 is a therapeutic vaccine against Alzheimer's disease. Alzinova's patented AβCC peptide technology makes it possible to develop disease-modifying treatments that target the toxic amyloid-beta oligomers that are central to the onset and development of the disease with great accuracy. From a global perspective, Alzheimer's disease is one of the most common and devastating neurological diseases, with around 40 million affected today. Based on the same technology, the company is also developing the antibody ALZ-201, which is currently in preclinical development, and the goal is to further expand the pipeline. The company's Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com